Gynaecology Unit, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UK.
Clínica Universidad de Navarra, Madrid, Spain.
ESMO Open. 2020 Nov;5(6):e001110. doi: 10.1136/esmoopen-2020-001110.
Poly(ADP-ribose) polymerase (PARP) inhibitor maintenance therapy is the latest breakthrough in the management of newly diagnosed advanced ovarian cancer. The results of the SOLO-1 trial in 2018 led to European Medicines Agency and Food and Drug Administration approval of olaparib as first-line maintenance therapy in patients with mutation, establishing a new standard of care. Subsequently, the results of three phase III trials (PRIMA, PAOLA-1, VELIA) evaluating the use of first-line PARP inhibitors beyond patients with mutations and as combination strategies were presented in 2019, leading to the recent approval of maintenance niraparib irrespective of biomarker status and olaparib in combination with bevacizumab in homologous recombination deficiency-positive-associated advanced ovarian cancer. An round-table expert panel discussed the four phase III trials of first-line PARP inhibitor therapy and how they are changing the clinical management of advanced ovarian cancer.
聚（ADP-核糖）聚合酶（PARP）抑制剂维持治疗是新诊断的晚期卵巢癌治疗的最新突破。2018 年 SOLO-1 试验的结果导致欧洲药品管理局和美国食品药品监督管理局批准奥拉帕利作为 突变患者的一线维持治疗，确立了新的治疗标准。随后，2019 年公布了三项评估一线 PARP 抑制剂在 突变患者以外的应用和联合治疗策略的 III 期临床试验（PRIMA、PAOLA-1、VELIA）的结果，最近批准了无论生物标志物状态如何，均可使用尼拉帕利维持治疗，以及奥拉帕利联合贝伐珠单抗治疗同源重组缺陷阳性相关的晚期卵巢癌。一个圆桌专家小组讨论了四项一线 PARP 抑制剂治疗的 III 期临床试验，以及它们如何改变晚期卵巢癌的临床管理。
